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INSIGHTS FROM MODEL SYSTEMS
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Eosinophils and neutrophils may be considered close
cousins, because of their shared bone-marrow origin,
circulation in the blood stream, and egress at tissue sites
of inflammation. Under the influence of distinct cyto-
kines, both eosinophils and neutrophils differentiate in
the bone marrow and enter the bloodstream. Both cell
types interact with the surface of inflamed endothelium,
diapedese between endothelial cells, and migrate
through the extracellular matrix at tissue sites of inflam-
mation, where they eventually release their stores of in-
flammatory mediators.
Although the trafficking patterns of neutrophils and
eosinophils from bone marrow to tissue sites of inflam-
mation have much in common, there are distinct differ-
ences in their association with different disease states.
For example, tissue recruitment of neutrophils is prom-
inent at sites of bacterial infection, whereas tissue re-
cruitment of eosinophils is prominent at sites of parasitic
infection and allergen challenge. The distinct patterns of
localization of these closely related circulating leuko-
cytes suggest that either the nature of the inflammatory
stimulus (i.e., bacteria, parasite, or allergen); the profile
of cytokines, chemokines, and mediators released in re-
sponse to the inflammatory stimulus; or the profile of
adhesion receptors and chemokine receptors expressed
by the eosinophil as compared with the neutrophil con-
tributes to their different tissue localization in response
to a particular inflammatory stimulus. An improved un-
derstanding of the factors responsible for the localization
of eosinophils at sites of allergic inflammationmay allow
for therapies for allergic inflammation that selectively
inhibit eosinophil tissue recruitment but that neither in-
fluence neutrophil tissue recruitment nor compromise
the host’s ability to defend against bacterial infection.
Asthma, a common respiratory disease affecting ∼3%
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of the U.S. population, is a disorder with a strong he-
reditary component but complex inheritance. The char-
acteristic features of asthma—airway inflammation,
bronchial hyperresponsiveness, and reversible airway
obstruction—arise in part through the activity of eosin-
ophil derived proinflammatory mediators, including a
stored granule component—major basic protein—as
well as cytokines and lipid mediators, which can be syn-
thesized at the site of inflammation (Broide et al. 1991,
1992; Weller 1997; Rothenberg 1998). These factors
contribute to airway smooth-muscle contraction, mucus
secretion, and denudation of the airway epithelium, all
of which are hallmarks of asthma. The importance of
the eosinophil in asthma and other allergic responses
has prompted considerable interest in the various stages
of eosinophil development, motility, and activation.
Here we discuss genetic and physiological studies that
have begun to clarify these events. At several points we
compare the properties of eosinophils with those of neu-
trophils, because of the clinical interest in therapies for
allergic asthma that might selectively suppress eosino-
phils while sparing neutrophils.
Eosinophil Differentiation: The Role of IL-5
Interleukin (IL)-5 plays at least two roles in the gen-
eration of blood-borne eosinophils. First, it stimulates
bone marrow CD34 progenitor cells, the precursors of
both eosinophils and neutrophils, to differentiate into
eosinophils. Second, it induces the mobilization of eo-
sinophils from the bone marrow into the bloodstream
(Palframan et al. 1998). The release of mature eosino-
phils from the bone marrow is a multistep process in-
volving the release of eosinophils from bone-marrow
stromal cells and extracellular matrix (ECM), the mi-
gration of eosinophils across the bone-marrow sinus en-
dothelium, and the release of eosinophils from the lu-
menal surface of the endothelium (Palframan et al.
1998). Once released, eosinophils traffic freely through
the bloodstream, until their surface receptors encounter
specific counterreceptor proteins that are expressed, by
the local endothelial cells, at sites of allergic inflam-
mation. Once bound firmly to such an endothelial-cell
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Watching a Drifter Change Its Ways
Classic studies of the interactions between leukocytes and en-
dothelial cells invariably have probed the binding of these cell
types in a static setting. Endothelial cells, plated as a monolayer,
were treated with stimulatory cytokines, and cells such as eo-
sinophils or neutrophils were introduced and allowed to bind
for a period of time. Such assays are limited in several respects,
perhaps most importantly in that they do not take into account
the effect that blood circulation has on leukocyte adhesion.
Intravital videomicroscopy provides a complementary in vivo
technique that allows one to visualize (and to record on vide-
otape) leukocyte trafficking as blood flows in the living vas-
culature of rabbits, mice, or rats. We have examined the pro-
gress of eosinophils through blood vessels in the skin, mes-
enteric circulation, and lung, and others have used similar tech-
niques to study cell migration in lymph nodes.
Intravital microscopy studies can be performed either onmice
that lack specific adhesion molecules or on wild-type animals
in which adhesion-blocking antibodies are introduced intra-
venously. Both approaches allow one to test the role of the
adhesion molecule in cell movement within the vessel. This
photomicrograph shows fluorescently labeled human eosino-
phils rolling and adhering to rabbit postcapillary venules. The
eosinophils, purified from peripheral blood, are injected intra-
venously into an anesthetized rabbit. The animal’s mesenteric
circulation is exteriorized so that it can be stimulatedwith either
an allergen or a specific cytokine such as IL-1 (to mimic aspects
of allergic inflammation) and be examined under stroboscopic
illumination using a videomicroscope. In the unstimulatedmes-
entery, eosinophils rarely interact with the endothelium but pass
freely through the circulation. In contrast, in the IL-1–stimu-
lated mesentery shown here, many of the eosinophils roll slowly
along the surface of the endothelium. Blood flow is from the
lower left to upper right. Noninteracting eosinophils (arrow-
heads) are captured in several discrete positions by successive
flashes of the stroboscope. In contrast, rolling eosinophils pro-
ceed more slowly along the endothelial surface and produce a
cometlike trail in the image. As discussed in the main text,
neutralizing antibodies to either L-selectin or a4 integrins—
eosinophil surface proteins that bind specifically to proteins on
the surface of the activated endothelium—significantly reduce
eosinophil rolling.
The electronic version of the Journal provides a videomicro-
graph of eosinophil rolling; see the Journal’s Website [http://
www.journals.uchicago.edu/AJHG/journal]).
surface, eosinophils are induced by inflammatory che-
mokines to migrate into tissue sites.
The recruitment of eosinophils into the airway can be
reproduced experimentally in mouse and human models
of allergen-induced asthma. In people sensitized to an
allergen such as house dust-mite allergen, inhalation
challenge with that allergen induces a significant airway
eosinophilic and IL-5 response 24 h later (Broide et al.
1992). IL-5–deficient mice are unable to develop eosin-
ophilia after allergen sensitization and challenge (Foster
et al. 1996). Moreover, studies that use DNA immuni-
zation to inhibit allergic inflammation (either because
the DNA encodes an allergen or because the noncoding
DNA contains a CpG sequence that serves as an adju-
vant that stimulates T-helper 1 cells ) recently have con-
firmed that DNA-mediated inhibition of IL-5 can sup-
press eosinophilic inflammation and bronchial
hyperresponsiveness in a mouse model of asthma (Hsu
et al. 1996; Broide et al. 1997, 1998b; Kline et al. 1998).
In humans, the IL5 gene is located on 5q31, and some
groups have reported 5q associations with asthma (Dan-
iels et al. 1996), autosomal dominant familial eosino-
philia (Rioux et al. 1998), and circulating eosinophil
levels (Martinez et al. 1998). Baranger et al. (1994) also
have identified chromosomal translocations involving
5q31-33, in malignancies associated with eosinophilia.
However, other candidate genes on chromosome
5q—such as the genes for the b2 adrenergic receptor, the
corticosteroid receptor, GM-CSF, IL-3, and IL-9—have
also been linked to asthma. Four genomewide screens
(Daniels et al. 1996; Collaborative Study of the Genetics
of Asthma 1997; Ober et al. 1997; Stine et al. 1998)
have identified a common set of loci (at 5q, 6p, 11q,
12q, 13q, and 16q) with probable linkage to suscepti-
bility to asthma, bronchial hyperresponsiveness, or al-
lergic inflammation. Despite this overall agreement,
none of the loci were identified by all four studies, and
several other loci were identified that may affect the
asthma phenotype in particular populations. These stud-
ies underscore the complex relationship of genes, the
environment, and the development of asthma in different
populations.
Regulation of Adhesive Interactions in Circulating
Eosinophils and Neutrophils
After inhalation of allergen, resident mucosal mast
cells and macrophages secrete cytokines, including IL-1,
IL-4, and tumor-necrosis factor (see Ruuls and Sedgwick
1999 [in this issue]). These cytokines act on neighboring
endothelial cells to up-regulate their expression of ad-
hesion molecules. Eosinophils in blood vessels may be
visualized in vivo by intravital videomicroscopy (see
sidebar). This research method demonstrates that eosin-
ophils interact with inflamed endothelium first by rolling
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Figure 1 Adhesion receptors mediating eosinophil rolling and firm adhesion to endothelium. Eosinophils use both integrin-mediated and
selectin-mediated adhesion for their initial rolling interaction with the endothelium (A), and they bind firmly to endothelium by using several
classes of integrins (B). Eosinophils differ from neutrophils in that they utilize a4b1 and a4b7 integrins to both roll and firmly adhere to VCAM-
1 expressed by endothelium. Their induction of firm adhesion depends in part on changes in the intrinsic affinity of these integrins for their
endothelial counterreceptors, the cell-adhesion molecules VCAM-1 and MAdCAM-1.
along their surface in the direction of blood flow and
then by adhering tightly to a single endothelial location
before transmigrating across the vessel and into the ablu-
menal tissue (Sriramarao et al. 1994, 1996). The first
step of the eosinophil/endothelial interaction is a low-
affinity tethering interaction between receptors ex-
pressed by the fast-flowing eosinophil in the blood
stream and counterreceptors expressed by inflamed en-
dothelium. This low-affinity interaction results in tran-
sient adhesion and detachment, permitting the eosino-
phil to roll along the endothelial surface sufficiently
slowly that it can respond to local biochemical cues that
promote firm adhesion. For example, the chemokine
eotaxin, which binds to the receptor protein CCR3 on
eosinophils, induces the eosinophil to arrest on endo-
thelium (Kitayama et al. 1998).
Considerable research has focused on understanding
the selective adhesion pathways that recruit eosinophils
to sites of allergic inflammation but that do not act on
neutrophils. As depicted in figures 1 and 2, the two cell
types share some adhesion pathways, but other molec-
ular interactions appear to be unique to eosinophils.
Both eosinophils and neutrophils express L-selectin and
P-selectin glycoprotein-1 (PSGL-1), and both cell types
use these cell-surface receptors to bind loosely (and,
hence, to roll) on counterreceptors expressed by inflamed
endothelium. Eosinophils, however, also use a4b1 inte-
grin and a4b7 integrin (receptors that are not expressed
on neutrophils) to roll on the endothelial surface protein
VCAM-1 (Sriramarao et al. 1994).
The importance of selectin adhesion molecules to neu-
trophil recruitment at sites of infection is suggested from
studies of patients with the congenital immunodeficiency
known as “leukocyte adhesion deficiency syndrome 2”
(LAD-2). Neutrophils from patients with LAD-2 lack a
critical enzyme in the biosynthesis of sialyl-Lewis X
(SLEX), a carbohydrate that binds specifically to E- and
P-selectins (Phillips et al. 1995). Because they lack SLEX,
neutrophils from patients with LAD-2 bind minimally
or not at all to E-selectin or P-selectin expressed by en-
dothelium, and they fail at the first step of tissue re-
cruitment to sites of bacterial infection, the induction of
rolling on the inflamed endothelial surface.
The endothelial-cell surface expresses adhesion
counterreceptors that bind either to both neutrophils
and eosinophils or selectively to a particular subset
of circulating leukocytes, to permit leukocyte rolling
(see figs. 1A and 2A). For example, both eosinophils
and neutrophils roll efficiently on P-selectin, but only
neutrophils can interact in this manner with E-selectin
(Sriramarao et al. 1996). Thus, in the first step of
leukocyte/endothelial interactions, there are both eo-
sinophil-specific interactions (a4b1 or a4b7 integrins
with the endothelial counterreceptor VCAM-1), neu-
trophil-specific interactions (SLEX with the endothe-
lial counterreceptors E- and P-selectin), and common
eosinophil and neutrophil interactions with endothe-
lial counterreceptors (PSGL-1 binding to P-selectin or
L-selectin binding to potential counterreceptors in-
cluding GlyCAM-1, CD34, or MAdCAM-1).
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Figure 2 Adhesion receptors mediating neutrophil rolling and firm adhesion to endothelium. Neutrophils rely on a different set of receptors
for their rolling (A) and their firm-adhesion (B) interactions with the endothelial surface. Congenital immunodeficiencies can arise from defects
in expression of neutrophil-adhesion receptors. Neutrophils from patients with LAD-1 do not express b2 integrins and thus cannot firmly adhere
to ICAM-1 expressed by endothelium. Because they lack SLEX, neutrophils from patients with LAD-2 bind minimally and do not roll on P-
selectin or E-selectin.
Firm adhesion, which prevents leukocyte detachment
from the endothelium despite the effects of blood flow,
is also controlled quite differently in eosinophils and
neutrophils (figs. 1B and 2B). Eosinophils bind tightly
both to ICAM-1 and to VCAM-1, whereas neutrophils
adhere tightly only to ICAM-1. Eosinophils express at
least three different integrin adhesion receptors—a4b1,
a4b7, and the recently identified adb2—that serve as re-
ceptors for endothelial VCAM-1 (Grayson et al. 1998).
In addition to the b1 integrins, eosinophils and neutro-
phils express three types of b2 integrins—collectively
known as “CD11/CD18”—that interact with ICAM-1.
All three types of b2 integrin receptors are heterodimeric
transmembrane proteins containing a unique a chain
and a shared b2 chain—that is, aLb2 (also known as
“CD11a/CD18” or “LFA-1”), aMb2 (also known as
“CD11b/CD18” or “Mac-1”), and aXb2 (also known as
“p150,95” or “CD11c/CD18”). Neutrophils, like eosin-
ophils, express CD11/CD18 b2 integrins and can bind
tightly to ICAM-1, but they lack a4b1 and a4b7 and thus
cannot bind to VCAM-1. Interestingly, in the congenital
immunodeficiency syndrome LAD-1, patients suffer
from recurrent bacterial infections and exhibit high pe-
ripheral-blood neutrophil-cell counts, but their tissue
neutrophils do not home to sites of infection. The mo-
lecular defect in these individuals has been identified in
the ITGB2 gene, which encodes the common b2 integrin
subunit. Neutrophils from patients with LAD-1 do not
express b2 integrins and thus cannot bind firmly to
ICAM-1 expressed by inflamed endothelium. Thus, neu-
trophils can enter the bloodstream from the bone mar-
row but cannot exit at sites of infection. Eosinophils
(cells that, like the neutrophils in such patients, lack b2
integrins) from patients with LAD-1 can bind normally
to endothelial VCAM-1, using a4b1 and a4b7, so they
can enter sites of inflammation even though they fail to
interact with ICAM-1.
Targeted ablation of mouse genes for these adhesion
receptors and the use of antibodies that block their ad-
hesion function confirm the importance of these adhe-
sion receptors in eosinophil recruitment. Using intravital
videomicroscopy (see sidebar), we have demonstrated
that eosinophil rolling and firm adhesion to endothe-
lium, as well as eosinophil tissue recruitment, are sig-
nificantly reduced in both P-selectin–deficient mice and
ICAM-1–deficient mice (Broide et al. 1998a). The sig-
nificance of the VCAM-1 adhesion pathway for eosin-
ophil recruitment is less clear and may vary in different
species (Abraham et al. 1994; Nakajima et al. 1994;
Henderson et al. 1997). Since eosinophils can use ICAM-
1–dependent pathways to bypass the need for VCAM-
1, it is not surprising that inhibition of VCAM-1 does
not completely abolish eosinophil recruitment.However,
neutralizing antibodies to a4 integrins improve airway
function in some animal models of asthma in which
eosinophil migration is only partially inhibited (Abra-
ham et al. 1994; Henderson et al. 1997). This effect may
be explained by the direct effects of the anti- a4 antibody
on proinflammatory responses of eosinophils or other
cell types expressing a4 receptors, as opposed to effects
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on adhesion. It is known that the portion of the alter-
natively spliced CS-1 exon of the ECM molecule fibro-
nectin binds a4b1. Ligation of this integrin activates eo-
sinophil expression of the cytokine GM-CSF, and the
blocking antibody to a4 inhibits this cytokine induction.
Hence, treatment with this anti-a4 antibody may affect
proinflammatory cytokine expression, as well as inter-
fere with eosinophil adhesion to the endothelium.
The ability of integrins such as a4b1 to mediate both
the early, rolling interaction with the endothelial surface
and the later, tight-adhesion function is consistent with
cell-culture studies in which the functional state of this
integrin is switched from a low-affinity to a high-affinity
state by cellular agonists. Sung et al. (1997), using a
single-cell micropipette adhesion assay, have demon-
strated that cytokines such as GM-CSF increase the af-
finity that eosinophil a4b1 has for both VCAM-1 and
CS-1. This change is not associated with altered integrin
expression level or surface cellular distribution, but it
appears to represent an increase in receptor avidity. GM-
CSF also affects b2-integrin–mediated interactions in eo-
sinophils, by up-regulating b2 expression, and it induces
the shedding of L-selectin from the surface of the eosin-
ophil. Thus, GM-CSF and, perhaps, other cytokines that
are released at sites of allergic inflammation appear to
control the adhesive properties of eosinophils, permit-
ting them to stop rolling over the endothelium and to
remain bound to it tightly in place.
Roles of Chemokines in Eosinophil Chemotaxis into
Tissues
Differential chemoattractant responses by eosinophils
and neutrophils to individual chemokines play an im-
portant role in the selective recruitment of endothelial
cell–adherent eosinophils and neutrophils to sites of in-
flammation. Chemokines have been classified into sub-
sets based on the position of the conserved cysteine res-
idues in their 8–10-kD amino acid sequence. CC
chemokines have two juxtaposed cysteine residues,
whereas CXC chemokines have an additional amino
acid (X) separating the two cysteine residues. As a rule,
neutrophils migrate in response to chemokines of the
CXC class, whereas eosinophils respond to CC che-
mokines. Several CC chemokines important to eosino-
phil recruitment are expressed at sites of allergic inflam-
mation after allergen challenge, and neutralizing
antibodies to CC chemokines or chemokine receptors,
as well as genetic ablation of CC chemokines, block
eosinophil recruitment. The chemokine eotaxin has gen-
erated considerable interest because of its specific effect
on eosinophils. Eosinophil recruitment is blocked early
after allergen challenge in eotaxin-deficient mice (Roth-
enberg et al. 1997), but not at later points in the process,
suggesting that other chemokines can function in this
pathway at later time points. Indeed, Gonzalo et al.
(1998) recently have shown that chemokines such as
RANTES, MCP-5, and MIP1a are also important in
eosinophil tissue recruitment.
The selectivity of the eosinophil response to a partic-
ular chemokine is due to the chemokine-receptor pro-
file expressed by eosinophils. Eosinophils predominantly
express the CCR3 receptor, to which eotaxin binds, with
lower levels of CCR1 (Kitaura et al. 1996; Ponath et al.
1996). Because RANTES and MCP-3 also bind to
CCR3, this receptor appears to be an attractive thera-
peutic target for inhibition of eosinophil recruitment,
particularly in light of the finding that neutralizing an-
tibodies to CCR3 block the binding of eotaxin, RAN-
TES, and MCP-2, -3, and -4 to human eosinophils
(Heath et al. 1997; Kitayama et al. 1998).
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